Martínez SCR, Rojas VG, Arias MA, Martínez RGJ

Language: Spanish
References: 19
Page: 23-30
PDF size: 327.29 Kb.

ABSTRACT

The evolution of reperfusion treatment has permitted an improvement in the prognosis and survival of patients with Acute myocardial infarction with ST elevation. The benefit of thrombolitic therapy was demonstrated clearly starting with the first trials of ISIS 2. It was also demonstrated this benefit is greater when the thrombolitic is combined with aspirin. Other trials have arisen like GUSTO I and TIMI 14, which have continued with the search for the best strategy of reperfusion, demonstrating that the pharmacologic combination with fibrinolitic, antiplatelet and antithrombinics provides the best results regarding permeability of the epicardic artery and transmiocardic reperfusion. Finally the mechanical reperfusion has managed to improve the results obtained with the pharmacologic treatment. Nevertheless it is probably that the Angioplasty with fibrinolitic and antiplatelet therapy is a useful treatment strategy, available for the patient with acute coronary syndrome with ST elevation. In light of the latest studies we must be very cautious, but based on the knowledge of the physiopathology of these syndromes, we think there is still much to discover.

REFERENCES

1. García-Castillo A, Jerjes SC, Martínez SC, Llamas EG, Cardona E, Barragán R, et al: Guías Clínicas para el Manejo del Infarto Agudo del Miocardio con elevación del segmento ST. Grupo de Trabajo Sociedad Mexicana de Cardiología y Asociación Nacional de Cardiólogos de México. Arch Cardiol Mex 2006; 76(Supl 3): 12-120.

2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349-360.

3. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. The GUSTO Investigators. N Engl J Med 1993; 329: 673-82.

4. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kliman NS, et al, for the TIMI 14 Investigators: Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-32.

5. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riba AL, Thompson MA, Rohrbeck S, Lundergan CF: For the PACT Investigators a randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 1999; 34: 1954-1962.

6. Herrmann HC, Moliterno DJ, Ohman ME, et al: Facilitation of early percutaneous coronary intervention after rateplase with or without abciximab in acute myocardial infarction. Results From the SPEED (GUSTO-4 Pilot) Trial (SPEED (GUSTO-4 Pilot) Trial PCI Substudy). J Am Coll Cardiol 2000; 36: 1489-96.

7. Martínez-Rios MA, Rosas M, Gonzalez H, Peña-Duque MA, Martínez Sánchez C, Gaspar J, et al: Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol 2004; 93: 280-7.

8. Sabatine MS, Cannon CP, Gibson CM, López-sendon JL, Montalescot G, Theroux P, et al, for the CLARITY-TIMI 28 investigators: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.

9. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E, ExTRACT-TIMI 25 Investigators: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-1488.

10. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial The GUSTO V Investigators. The Lancet - Vol. 357, Issue 9272, 16 June 2001, Pages 1905-1914

11. Antman EM, Van der Werf F: Pharmacoinvasive therapy. The future of treatment for ST-Elevation Myocardial Infarction. Circulation 2004; 109: 2480-2486.

12. Jerjes Sánchez C, López M, Villarreal S, et al: Terapia fibrinolítica en Infarto con elevación del ST y Tromboembolia Pulmonar. México 2006: ISBN 970-91546-5-6.

13. Primary versus tecenteplase – facilitated percutaneous coronary intervention in patients with ST – segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomized trial Investigators. Lancet 2006; 367: 569-576.

14. Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators: Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004; 147(4): E16-22.

15. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, Vazquez N, Blanco J, Alonso-Briales J, Lopez-Mesa J, Fernandez-Vazquez F, Calvo I, Martinez-Elbal L, San Roman JA, Ramos B; GRACIA (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Group: Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomized controlled trial. Lancet 2004; 364: 1045–53.

16. Fernandez-Aviles F, Alonso JJ, Pena G, Blanco J, Alonso-Briales J, Lopez-Mesa J, Fernandez Vazquez F, Moreu J, Hernandez RA, Castro-Beiras A, Gabriel R, Gibson CM, Sanchez PL: Primary angioplasty vs early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA 2 non-inferiority, randomized, controlled trial. Eur Heart J 2007; 0: ehl461v1-12.

17. Villafaña I, Arias A, Martínez Sánchez C, González PH, Lupi E, Juárez U, et al: Resultados a 30 días en pacientes con IAM con elevación del segmento ST, que presentaron criterios de repercusión y que fueron llevados a intervencionismo en forma temprana. Libro de resúmenes trabajos orales y en cartel del XXIV Congreso Nacional de Cardiología, XX Congreso Interamericano de Cardiología. Arch Cardiol Mex 2005; 75(Supl 4): S4-S5.

18. García-Castillo A, Jerjes-Sánchez C, Martínez BP, Azpiri-López JR, Autrey AC, Martínez Sánchez C, et al: Registro Mexicano de Síndromes Coronarios Agudos RENASICA II. Arch Cardiol Mex 2005; 75(Supl 1): 6-32.

19. Martínez-Sánchez C, Arias MA, González PH, Rojas-Velasco G: Síndromes Isquémicos Coronarios Agudos. México. Ed Intersistemas, 2007: 81-116.